Novartis Clozaril, Generic Registry Merger Could Clarify Potential Risk
Executive Summary
Combining Novartis' Clozaril white blood cell patient registry with generic clozapine databases could provide a clearer picture of the potential risk of moving to a less frequent monitoring schedule, FDA's Psychopharmacologic Drugs Advisory Committee agreed June 16
You may also be interested in...
Tysabri Registry Monthly Reports And Patient Checklist Follow-Up Advised
Biogen Idec should receive monthly reports from its Tysabri risk management patient registry on checklists filled out prior to infusion, members of FDA's Peripheral & Central Nervous System Drugs Advisory Committee recommended March 8
Tysabri Registry Monthly Reports And Patient Checklist Follow-Up Advised
Biogen Idec should receive monthly reports from its Tysabri risk management patient registry on checklists filled out prior to infusion, members of FDA's Peripheral & Central Nervous System Drugs Advisory Committee recommended March 8
Risk Management Cloud Rains On Praecis, Offers Silver Lining To Novartis
Brand loyalty stemming from Novartis' risk management program for Clozaril (clozapine) has limited generic erosion for the antipsychotic, Novartis Medical Information & Communication Exec Director Tom Gesell said